Evidence map›Paper›PMID 30309325›Full record

ArticleBMC cancer2018

Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.

Laurie L Brunette, Paulette Y Mhawech-Fauceglia, Lingyun Ji, Joseph G Skeate, Heike E Brand, Kate Lawrenson, Saloni Walia, Maurizio Chiriva-Internati, Susan Groshen, Lynda D Roman and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Nucleic acid vaccination strategies for ovarian cancer.Frontiers in bioengineering and biotechnology · 2022
    Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Laurie L BrunetteDepartment of Obstetrics & Gynecology, University of Southern California, 1450 Biggy Street, Los Angeles, CA, 90033, USA.
Paulette Y Mhawech-FaucegliaDepartment of Pathology, University of Southern California, California, Los Angeles, USA.
Lingyun JiNorris Comprehensive Cancer Center, University of Southern California, California, Los Angeles, USA.
Joseph G SkeateDepartment of Molecular Microbiology & Immunology, University of Southern California, California, Los Angeles, USA.
Heike E BrandNorris Comprehensive Cancer Center, University of Southern California, California, Los Angeles, USA.
Kate LawrensonDepartment of Obstetrics & Gynecology, Cedars-Sinai Medical Center, California, Los Angeles, USA.
Saloni WaliaDepartment of Pathology, University of Southern California, California, Los Angeles, USA.
Maurizio Chiriva-InternatiDepartment of Myeloma and Lymphoma, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Susan GroshenNorris Comprehensive Cancer Center, University of Southern California, California, Los Angeles, USA.
Lynda D RomanDepartment of Obstetrics & Gynecology, University of Southern California, 1450 Biggy Street, Los Angeles, CA, 90033, USA.
W Martin KastDepartment of Obstetrics & Gynecology, University of Southern California, 1450 Biggy Street, Los Angeles, CA, 90033, USA.
Diane M Da SilvaDepartment of Obstetrics & Gynecology, University of Southern California, 1450 Biggy Street, Los Angeles, CA, 90033, USA. diane.dasilva@med.usc.edu.ORCID http://orcid.org/0000-0001-7317-4886
University of Southern California · USCedars-Sinai Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

backgroundPrior small studies have shown increased expression of sperm protein 17 (Sp17) in epithelial ovarian cancer (EOC) tissue and suggest Sp17 as a potential biomarker for EOC. However, how Sp17 expression varies with histology, grade, and stage of EOC and its expression in other ovarian neoplasms has not been defined. It is unknown whether patients with EOC have elevated serum Sp17 levels or if Sp17 expression is associated with survival outcomes.

methodsThe study included 982 patients with benign, borderline, and malignant ovarian neoplasms and normal ovary. There were 878 patients with tissue only, 39 with serum only, and 65 with matching serum and tissue. Immunohistochemical (IHC) staining with anti-Sp17 antibody was performed on tissue specimens and the intensity scored as weak, moderate, or strong. A sandwich enzyme-linked immunosorbent assay (ELISA) was performed to measure Sp17 sera concentrations.

resultsSp17 expression was most commonly seen in serous cystadenomas (83%) and serous borderline tumors (100%). Of the 773 EOC specimens, 223 (30%) expressed Sp17. Grade and histology were significantly associated with Sp17 expression among EOC specimens (p < 0.001) on both univariate and multivariable analysis, with grade 1 serous adenocarcinomas showing the highest expression (51%). Sp17 expression was limited in other benign and non-epithelial malignant neoplasms. Neither Sp17 tissue expression nor serum concentration correlated with survival outcomes. Serum concentrations were higher in patients with Sp17 tissue expression, and the highest concentrations were noted among patients with serous and clear cell adenocarcinomas.

conclusionsSp17 is highly expressed in benign, borderline, and low grade malignant serous ovarian neoplasms and can be quantified in serum. Sp17 expression may have diagnostic significance in this subset of patients.

Indexed as

AdolescentAdultAgedAged, 80 and overAntigens, SurfaceBiomarkers, TumorCalmodulin-Binding ProteinsCarcinoma, Ovarian EpithelialCarrier ProteinsCell Line, TumorChildCystadenoma, SerousFemaleHumansMembrane ProteinsMiddle AgedAntigens, SurfaceBiomarkers, TumorCalmodulin-Binding ProteinsCarrier ProteinsMembrane ProteinsSPA17 protein, humanBorderline ovarian tumorEpithelial ovarian cancerOvarian biomarkerSerousSperm protein 17

Identifiers

PMID30309325
PMCPMC6182788
OpenAlexW2896528779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.